Evaluating Myelodysplastic Syndrome Risks in NET Patients Planned for Peptide Radionuclide Therapy

Abroad (travel likely)Recruiting

Conditions

Myelodysplastic Syndrome · Acute Myeloid Leukemia

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Contact: Study coordinator (Rebecca Wong, MD) · rebecca.wong@rmp.uhn.on.ca · 416-946-4501

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases

Acute Leukemia of Ambiguous Lineage · Acute Lymphoblastic Leukemia · Acute Myeloid Leukemia

Abroad (travel likely)RecruitingPHASE2

Seattle, United States

Tagraxofusp and Azacitidine for Maintenance Treatment in Patients With CD123 Positive AML and MDS Following Donor Hematopoietic Cell Transplant

Acute Myeloid Leukemia · Myelodysplastic Syndrome

Abroad (travel likely)RecruitingPHASE1

Duarte, United States

A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma

B-Cell Non-Hodgkin Lymphoma · Histiocytic and Dendritic Cell Neoplasm · Myelodysplastic Syndrome

Abroad (travel likely)RecruitingPHASE1

Scottsdale, United States · Rochester, United States

Haplo-Cord HSCT for AML/MDS

MDS (Myelodysplastic Syndrome) · AML (Acute Myeloid Leukemia)

Abroad (travel likely)Recruiting

Fuzhou, China · Guangzhou, China